Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Hoffmann-La Roche
Wake Forest University Health Sciences
EMD Serono
M.D. Anderson Cancer Center
University of California, San Diego
Merck Sharp & Dohme LLC
Dana-Farber Cancer Institute
Boehringer Ingelheim
Radiation Therapy Oncology Group
Boehringer Ingelheim
Eli Lilly and Company
Varian, a Siemens Healthineers Company
I-Mab Biopharma US Limited
University of Colorado, Denver
Incyte Corporation
Dana-Farber Cancer Institute
Tempus AI
University of Kentucky
University of Arkansas
Sanford Health
EMD Serono
University of Pennsylvania
Massachusetts General Hospital
University of Wisconsin, Madison
Palleon Pharmaceuticals, Inc.
Incyte Corporation
MacroGenics
The University of Texas Health Science Center at San Antonio
Incyte Corporation
GERCOR - Multidisciplinary Oncology Cooperative Group
Icahn School of Medicine at Mount Sinai
University of California, San Diego
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
Medical College of Wisconsin
University of California, San Diego
University of Colorado, Denver
Hoffmann-La Roche
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
Alume Biosciences, Inc.
VA Office of Research and Development
Thomas Jefferson University
M.D. Anderson Cancer Center
Elevation Oncology
GeoVax, Inc.
Wake Forest University Health Sciences
University of Pittsburgh
Intensity Therapeutics, Inc.